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ABSTRACT 
Osteoporosis is a condition that decreases bone density and is more commonly found in 
elderly women due to estrogen depletion. The decrease in bone density puts patients at risk for 
fragility fractures, or fractures with minimal impact, which can drastically alter patients’ lives. 
Primary prevention of these fractures is the goal with pharmacologic therapy for osteopenia or 
osteoporosis. There are many treatment options for osteoporosis and most are considered cost 
effective for patients with high fracture risk due to decreased bone density. Treatment decisions 
for osteopenia or osteoporosis are now based upon a fracture risk assessment tool in addition to 
T-score values. Studies have demonstrated that adherence to pharmacologic therapy to decrease 
fracture risk and maintain bone density is an issue with the majority of patients. Most patients are 
not staying on treatment for greater than one year for a variety of reasons. A practice 
improvement project was conducted at an internal medicine private practice clinic that serves 
10,000 patients in a Midwestern community. The project included retrospective chart reviews 
and key informant interviews in order to gain expanded knowledge of the issue and provide 
recommendations for improvement.  
Results showed inconsistent documentation of patient treatment preferences and provider 
treatment decisions. Additional areas for improvement included patient and provider follow up 
of treatment decisions as well as patient education regarding the disease process and benefits of 
treatment. Results and recommendations for improvement were disseminated to providers at the 
clinic with feedback solicited. An electronic medical record change was implemented in order to 
improve documentation of treatment decisions regarding elevated fracture risk. 
The results of the project may not be transferrable due to small sample size and area of 
focus at one Midwest clinic. However, themes regarding clinical decision-making and 
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documentation of osteoporosis treatment emerged that likely exist at other primary care clinics. 
Further research is needed in order to evaluate effectiveness of electronic medical record 
intervention at the clinic. Other opportunities for further research involve expanding the topic to 
larger healthcare organizations and other areas of the country for comparison. 
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CHAPTER ONE. BACKGROUND AND SIGNIFICANCE 
Osteoporosis Defined 
Osteoporosis is a condition that decreases the density of bones resulting in weaker bones 
and greater risk of fragility fractures. Fragility fractures occur with less force than may be 
expected in the fracture of a normal bone, usually including falls from standing height or less. 
Risk factors for the development of osteoporosis include aging, estrogen deficiency, low calcium 
and vitamin D intake, and certain disorders (Bolster, 2015). 
Fragility Fractures 
Prevention of fractures from osteoporosis is imperative because they can devastate the 
lives of patients. One out of five of people who suffer a hip fracture die within a year of the 
fracture and the risk of death persists for up to five years following the fracture. Hip fractures 
often result in the loss of physical functioning and independence for patients. Thirty-three 
percent of patients are totally dependent for activities of daily living in nursing homes following 
hip fractures. Vertebral fractures can also dramatically change lives, leading to back pain, height 
loss, physical deformity, immobilization, increased time in bed, and reduced lung functioning. 
Not only can fragility fractures drastically alter lives, there is also a socioeconomic impact. 
Fragility fractures increase costs for hospital and surgical care and indirectly result in loss of 
productivity for patients with loss of independence and need of nursing home or institutional 
care. If actively employed, these fractures can result in a loss of workdays and productivity 
(International Osteoporosis Foundation, 2015). Osteoporosis and subsequent fractures can be 
reduced with adequate calcium and vitamin D intake, weight bearing exercise, and 
pharmacologic therapy (Bolster, 2015). 
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Dual-Energy X-ray Absorptiometry 
Since patients with osteoporosis are usually asymptomatic until a fracture occurs, 
diagnosis is achieved with dual-energy x-ray absorptiometry (DXA) screening or with DXA 
confirmation after a fragility fracture. DXA measures bone mineral density (BMD) and providers 
can diagnose a patient with osteopenia or osteoporosis based on results. DXAs also predict 
fracture risk and can be used to monitor treatment response (Bolster, 2015).  
Results of DXA scans are given using three values, T-score, Z-score, and fracture risk 
assessment score. T-scores represent the standard deviations that the patient’s bone density 
differs from a young, healthy individual of the same sex and ethnicity with peak bone mass. T-
scores of < -1.0 to > -2.5 signify osteopenia and  -2.5 signify osteoporosis. Z-scores represent 
the number of standard deviations the patient’s BMD differs from someone of the same age and 
sex. Z-scores should be used for children, pre-menopausal women, and men less than 50 years 
old. Z-scores  -2.0 should be evaluated for secondary causes of bone loss. Historically, 
osteoporosis treatment decisions were based on T-score values alone, however, it has been 
realized in recent years that T-score values are not the optimal way to measure fracture risk, 
because many fragility fractures occur in people outside the T-score ranges, most occurring 
within the osteopenia range (Bolster, 2015). According to the National Osteoporosis Risk 
Assessment study, there were 2259 post-menopausal women who sustained fragility fractures 
and had a follow-up DXA scan one year later; 82% of these women had a T-score value above    
-2.5 and 67% had a T-score value above -2.0.  
Fracture Risk Assessment Tool 
The University of Sheffield developed the fracture risk assessment tool (FRAX) in 2008 
to incorporate risk factors for osteoporosis with or without femoral neck BMD to calculate a 
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patient’s 10-year risk of fragility fractures (Bolster, 2015). The decision for treatment of 
osteopenia is now based on FRAX scores in addition to T-score values. FRAX scores can be 
calculated either with or without BMD testing (DXA score).  
Osteoporosis Guidelines and Screening Recommendations 
According to the National Osteoporosis Foundation’s “Clinician’s Guideline for the 
Prevention and Treatment of Osteoporosis” (2014) patients with a total fracture risk of ≥ 20% or 
a hip fracture risk of ≥ 3% and a T-score value between -1.0 and -2.5 should have pharmacologic 
therapy recommended because it is considered cost effective for the primary prevention of 
fragility fractures. In addition to these recommendations, there are two other scenarios patients 
should be initiated on treatment. The first is if there is a prior or current history of clinical or 
asymptomatic vertebral fractures or hip fractures. In addition, if a patient’s T-score is below -2.5, 
treatment should be initiated unless otherwise contraindicated (Cosman et al, 2014). 
According to the United States Preventative Services Task Force (USPSTF) (2016), 
screening for osteoporosis using DXA scans is recommended for women greater than 65 years of 
age. Women 50-64 years old should have DXA screening recommended if their FRAX score is 
greater than or equal to 9.3%. The reason for the 9.3% is that the fracture risk is equal to a 65-
year-old woman who has no additional risk factors. There is currently no recommendation for 
osteoporosis screening in men. Currently, the USPSTF (2016) has no recommendation for 
frequency of DXA rescreening due to lack of sufficient evidence. The interval for rescreening 
should be based on clinical judgement, but the American Family Physician’s guidelines entitled, 
“Diagnosis and Management of Osteoporosis” (2015) recommend screening no more than every 
one to two years. The recommendations by the USPSTF (2016) are graded level “B”, meaning 
that clinicians should recommend or provide the service based on high certainty that the net 
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benefit for the population is moderate. The USPSTF determines the net benefit based on 
available evidence that is sufficient to determine the effect of the recommended service, 
however, confidence is constrained due to factors such as the sample size, quality, or quantity of 
studies, inconsistency of results from studies, limited generalizability to primary care, or lack of 
coherence among the evidence (USPSTF, 2017). 
Project Introduced 
Many patients think of osteoporosis as a “silent disease” and do not see the benefit in 
receiving medication for primary fragility fracture prevention. Adherence to pharmacologic 
therapy remains the largest treatment issue for providers. Studies have demonstrated that after 
one year of therapy only 40% of patients remain on the medication and after two years only 20% 
remain on the medication (International Osteoporosis Foundation, 2015a).  
For the practice improvement project, attention was focused on an independent internal 
medicine clinic serving around 10,000 patients in a Midwestern community. Retrospective chart 
reviews and key informant interviews were conducted to identify treatment patterns of patients 
with significant fracture risk (≥ 3% hip fracture risk and or ≥ 20% major fracture risk). The focus 
of the project was to increase awareness of providers and identify contributing factors to 
inadequate treatment in the targeted population. Providers at the participating clinic were 
included in the project, with the goal of inspiring sustainable change and improvement in 
osteoporosis management, ultimately decreasing morbidity and mortality of affected patients. 
Significance of Practice Improvement Project 
If patients with significant fracture risk are not receiving pharmacologic therapy, they 
may have an increased risk of fragility fractures, which can ultimately decrease their quality of 
life and increase mortality. The overall purpose of the practice improvement project was to 
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increase awareness of the lack of pharmacologic treatment of patients with significant fracture 
risk or identify patterns in current osteoporosis treatment and barriers to optimal osteoporosis 
management to providers at an independent internal medicine clinic that serves 10,000 patients 
in a Midwestern community. The goal is that with the awareness and recommendations for 
improvement the providers will make future practice changes and increase the proportion of 
patients on treatment.  
Congruence of the Project to the Organization’s Strategic Goals 
The internal medicine clinic where the project was conducted specializes in internal 
medicine services for the adult patient. The clinic staff provides primary, preventative and 
specialty services. One of the clinic’s commitments to their patients is, “We’ll offer a preventive 
approach to help you achieve and maintain the highest quality of health possible for you.” With 
the commitment in mind, prevention of fragility fractures from osteoporosis is something that is 
taken very seriously within the organization.  
In discussion with one of the clinic’s physician owners who has a strong interest in 
osteoporosis, a project focusing on osteoporosis management was one of high importance. The 
clinic’s office manager was also a very important part of the project and contributed by 
providing the researcher with necessary access and data throughout all stages of the project.  
Project Objectives 
Objective One: Complete a retrospective chart analysis to determine gaps, barriers, and 
successes related to osteoporosis management at an internal medicine clinic in a Midwestern 
community. 
Objective Two: Conduct key informant interviews with healthcare providers to 
supplement chart analysis findings regarding osteoporosis management. 
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Objective Three: Develop recommendations for improvement based upon retrospective 
chart analysis and key informant interviews. 
Objective Four: Disseminate the findings of chart reviews and key informant interviews 
to providers at the internal medicine clinic and provider recommendations for improvement. 
Objective Five: Implement an electronic medical record (EMR) change in order to 
improve documentation of non-treatment reasons and/or improve the proportion of patients 
receiving treatment in the future. 
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CHAPTER TWO. THEORETICAL FRAMEWORK 
Theory of Power as Knowing Participation in Change 
Nursing theories have many important implications for practice, including but not limited 
to furthering theory development, providing perspective about certain human behaviors, a means 
to interpret data, and they are inherently useful for guiding practice (Peterson & Bredow, 2013). 
The theory chosen to guide the project is the Theory of Power as Knowing Participation in 
Change by Dr. Elizabeth Barrett (2009). The theory defines power as “the capacity to participate 
knowingly in change as manifested by awareness, choices, freedom to act intentionally, and 
involvement in creating change (Barrett, 2009).” The definition also includes the theory’s four 
dimensions of power. The theory also differentiates two types of power, power-as-control and 
power-as-freedom. Power-as-control is grounded in the laws of cause and effect and 
characterized by being hierarchal and predictable. Power-as-control is of finite quantity, in 
contrast to power as freedom, which is an open universe where power is not of finite quantity. 
Power-as-freedom is characterized by innovation, openness, and unpredictability. There are 
numerous examples of how knowledge is utilized in the world for both freedom or control, for 
example, money can be used in order to control others in a form of power, or it can be used for 
freedom such as charitable giving. In the same ways, power can be used for both control and 
freedom. Dr. Barrett defines power as the ability to participate knowingly in change; she sees 
power as a process to be lived rather than something to be acquired (Barrett, 2009).  
The theory was chosen to guide the project because it involves an attempt to create 
change in a healthcare establishment to improve osteoporosis management. With Dr. Barrett’s 
theory to guide the project, we can help more fully understand what we need to have the power 
to change knowingly. Through the needs assessment that was conducted at the internal medicine 
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clinic, the awareness portion of the theory was achieved by disseminating results of the chart 
analysis and interviews to the health care providers at the clinic. Providers at the clinic are 
committed to high-quality patient care, so a needs assessment, which reveals suboptimal 
osteoporosis care, would be important information to spur practice change. Through the needs 
assessment, information was gathered, identifying possible reasons for patients not receiving 
treatment. The findings were presented to the providers. The dissemination leads to the choices 
portion of Dr. Barrett’s theory. The choices included the recommendations for improvement 
presented to providers. Freedom to act intentionally involves the providers at the clinic actively 
making the choice to change their practice based on these choices. The last portion of the theory 
revolves around creating change, which will come to fruition when providers actually make 
changes to their practice based on the choices and freedom to act intentionally. Dr. Barrett’s 
theory was very beneficial for the guidance of the project. A breakdown of how the theory was 
used to guide the project can be found in figure 1. 
 
Figure 1. A graphic representing the application of Dr. Barrett’s Theory of Power as Knowing 
Participation in Change. 
Awareness
•Results of needs assessment & 
interviews
Choices
•Recommendations for 
improvement
•Providers recognizing a need 
for change
Freedom to Act Intentionally
•Electronic medical record change
•Providers making the choice to 
make changes to their practice
Involvement in Creating Change
•Providers making changes to their 
practice based on recommendations
•Providers accepting EMR change 
and recognizing benefit
•Dissemination Evaluation Results
Power as 
Freedom or 
Control
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CHAPTER THREE. LITERATURE REVIEW 
Adherence to Treatment 
The International Osteoporosis Foundation (2015) reports osteoporosis as the cause of 
more than 8.9 million fractures annually which equates to one fracture every three seconds. One 
out of three women over the age of 50 will experience an osteoporotic fracture as well as one out 
of five men the same age. A critical aspect of osteoporosis management is identifying and 
treating patients who are at the highest risk for fractures before they have sustained one. 
Successful osteoporosis management reduces the risk of first time fracture in 5 years from about 
34% to 10%. Osteoporosis treatment to prevent fractures is a difficult task for many reasons, 
including cost, side effects, patient perception of efficacy and safety, perceived lack of benefit, 
preference of “natural” treatment in calcium and vitamin D, and complicated dosing instructions 
(Warriner & Curtis, 2009). 
Another major reason behind the lack of pharmacologic treatment of osteoporosis is a 
generalized low public awareness of the morbidity and mortality associated with untreated 
osteoporosis and subsequent fragility fractures. In a review by Harvey et al. (2017), three areas 
of public awareness in relation to osteoporosis were identified as in need of improvement. The 
areas in need of improvement for the public were the importance of adherence to treatment, 
osteoporosis diagnosis and fracture risk, and benefits versus risk of pharmacologic treatment. 
Public awareness of the potential morbidity and mortality risk of untreated osteoporosis is 
another area that needs to be addressed to increase the overall adherence and acceptance of 
pharmacotherapy for patients with fracture risk. 
There are a wide variety of treatment options for osteoporosis, which can reduce risk of 
vertebral fractures by 30 - 70%, non-vertebral fractures by 15 - 20%, and hip fractures by 40%. 
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The treatment options are cost effective and have proven rapid efficacy for prevention of these 
fractures. However, poor compliance is one of the main issues with treatment (International 
Osteoporosis Foundation, 2015a). A study by Zwaard et al. (2017), demonstrated that after one 
year of therapy, only 75% of patients remain on the medication and after five years of therapy 
only 45% remain on treatment. According to the study, the main reasons associated with patients 
not persisting with therapy included age less than 65 and a specialist being the main prescriber. 
The patients with a general practitioner as the main prescriber were more persistent with 
treatment (45%) than those with a specialist main prescriber (39%) after five years of therapy 
(Zwaard, 2017). The study demonstrates the importance of primary care providers being 
comfortable with the screening and management of osteoporosis as it has been associated with 
better adherence to treatment by patients. 
An article by LaVallee et al (2016), titled “The Challenges in the Screening and 
Management of Osteoporosis” further explores possible reasons that patients may not be 
prescribed appropriate pharmacologic management for osteoporosis. There is a lack of 
confidence among primary care providers when it comes to determining patients needing 
pharmacologic therapy and how long to treat the patient with increased fracture risk. The 
decision regarding length of therapy was further complicated when information about possible 
risks of atypical femur fractures and osteonecrosis of the jaw were released, as these risks 
indicated a need for drug holidays from the commonly used bisphosphonates. The length and 
choice of therapy is an especially difficult problem to address because of the lack of access to 
specialty care since osteoporosis is such a common disease process. Primary care providers also 
seem to struggle with the interpretation of DXA scan results and recommending the proper 
course of treatment (LaVallee et al., 2016). Overall, primary care providers need to become more 
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comfortable and confident in the screening and management of osteoporosis if we want our 
patients to adhere to treatment. 
Several patient factors also contribute to the lack of pharmacologic therapy for the 
treatment of osteoporosis. These include a lack of understanding of the disease process, concern 
over using medication to treat a “silent” disease to prevent a possible future outcome, concern 
over possible side effects of the medication, and the cost of therapy. First, patients have a 
generalized poor understanding of the possible morbidity and mortality associated with untreated 
osteoporosis. It is up to providers to educate patients about the disease process as well as 
possible consequences of fragility fractures. Unfortunately, even after such discussions patients 
often still chose to “wait and see”, treat with diet and exercise, or refuse treatment altogether 
(LaVallee et al., 2016). 
Many patients have a hard time buying into the use of another medication to treat a 
disease that they feel is “silent” in nature. The patient decision to treat is especially difficult in 
the elderly who may already be taking many medications. These patients often believe that they 
can treat osteoporosis with diet and exercise alone and refuse the pharmacologic therapy. Often, 
having conversations with patients regarding the maintenance of independence and quality of life 
carries more weight than quoting statistics about morbidity and mortality (LaVallee et al., 2016). 
Pharmacologic Treatment Options for Osteoporosis 
There are many different treatment options for osteoporosis management. 
Bisphosphonates are the most commonly used agents. The reasons that bisphosphonates are used 
first-line and most commonly is because many insurance companies require that patients fail 
bisphosphonates or have a medical reason why the medications should not be utilized for that 
patient prior to covering the other types of treatment modalities. Bisphosphonates inhibit the 
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bone resorption activity of osteoclasts by attaching to hydroxyapatite binding sites located on 
bony surfaces (Rosen, 2017). They are available orally or intravenously and depending on the 
agent can be dosed daily, weekly, monthly, four times a year, or annually. The most common 
side effects from oral bisphosphonates are related to gastrointestinal issues such as esophageal 
ulcerations, perforations, and bleeding events. The medications must be taken with water and the 
patient must sit up for at least 30 minutes after taking the medication or taking in any other 
medication or food. Taking the medications this way reduced the risk of gastrointestinal upset 
and allowed for effective absorption. Other common side effects from these medications include 
muscular and joint pain (Jeremiah et al., 2015). The bisphosphonate agents include alendronate, 
risedronate, ibandronate, and zoledronic acid.  
There are questions concerning length of therapy associated with bisphosphonates. 
Limited trial data is available for the long-term management with bisphosphonates. The length of 
treatment becomes more important and challenging with newly recognized rare side effects of 
bisphosphonates including osteonecrosis of the jaw and atypical femoral fractures (Bethel et al., 
2017). The risk of these side effects is very rare, the estimated risk of osteonecrosis of the jaw for 
patients treated with zoledronic acid is 0.017 - 0.04% compared to placebo group risk of 0 - 
0.02% (Ruggiero et al., 2014). Malden et al. (2012) derived an incidence of osteonecrosis of the 
jaw after exposure to oral bisphosphonates as 0.4 cases per 10,000 patient years. The risk of 
osteonecrosis of the jaw was more common when these medications were used to treat different 
types of bone cancer, when used for the treatment of osteoporosis at much lower doses, the risk 
was very rare (Udell, 2017). The risk of atypical femoral fractures is 0.13% in the following year 
in patients who have been treated for at least 5 years (Park-Wyllie et al., 2011).  
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Despite the rarity of these side effects, they have received a large amount of media focus 
(LaVallee et al., 2016). For these reasons, the American Society for Bone and Mineral Research 
(2016) published guidelines for long-term bisphosphonate treatment with the following 
recommendations. Reassessment of risk should be assessed after five years of oral or three years 
of injectable bisphosphonate therapy. Women considered high risk (older age, low hip T-score, 
high FRAX score, previous fragility fracture, fracture while on therapy) should continue 
treatment for up to ten years with oral agents or six years with intravenous agents with periodic 
reassessment. The risk of atypical femoral fracture and osteonecrosis of the jaw increases with 
the duration of therapy, but the rare event risk is outweighed by the benefit of fragility fracture 
risk reduction in high-risk individuals. Lastly, women not at high fracture risk should have a 
drug holiday of 2-3 years after 3-5 years of bisphosphonate therapy (Adler et al., 2016). As you 
can see, even though these side effects are considered rare, there are guideline recommendations 
in place to help providers minimize these risks as much as possible. Patients need to be aware of 
these recommendations and the research behind them so that they can be fully informed about 
their treatment decisions. 
Selective estrogen receptor modulators (SERM) are another agent used in the treatment 
of osteoporosis. Raloxifene (Evista) selectively binds to estrogen receptors producing estrogenic 
and anti-estrogenic effects, it acts as an estrogen agonist in bone decreasing bone resorption and 
turnover (Epocrates, 2017). Raloxifene is an oral SERM agent approved for the use in 
osteoporosis management and is dosed once daily. Raloxifene has demonstrated a 35% reduction 
in risk of vertebral fractures in clinical trials and seems to be most useful in younger 
postmenopausal women. Raloxifene has been shown to increase risk of deep vein thrombosis, 
stroke, and hot flashes (Bethel et al., 2017). 
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Teriparatide (Forteo) is synthetic parathyroid hormone that is used in the treatment of 
osteoporosis in patients with high fracture risk who are intolerant to other osteoporosis therapy, 
or whom previous osteoporosis therapy has failed to increase BMD. Teriparatide is a daily 
injection administered subcutaneously. Teriparatide works in osteoporosis management by 
regulating bone metabolism, intestinal calcium absorption, and reabsorption of renal tubular 
calcium and phosphate (Epocrates, 2017). Teriparatide cannot be given for more than 2 years. 
After 2 years, the gains in BMD have been achieved and are secure. Longer treatment would 
result in the BMD regressing to pre-treatment levels. After the 2-year course of treatment, 
patients can be augmented with bisphosphonate therapy (Bethel et al., 2017). 
Calcitonin-salmon (Fortical, Miacalcin) decreases osteoclast activity, inhibiting bone 
loss. It is indicated for the treatment of osteoporosis in women who are more than 5 years post-
menopausal and have low bone mass. Calcitonin should be reserved for those who refused, 
cannot tolerate, or contraindicated for estrogen use. The drug is dosed daily as an intranasal 
spray (Bethel et al., 2017). In 2013, the United States Food and Drug Administration (FDA) 
showed an increased risk of malignancy in calcitonin treated patients. The data from the study 
was not sufficient to further analyze by the type of malignancy associated and a definitive causal 
relationship between calcitonin and malignancy could not be established. The FDA now 
recommends that health care providers assess each patient’s need for osteoporosis therapy and 
weigh the risks versus benefits (United States FDA, 2015). Also, it has been demonstrated that 
calcitonin is not as potent or effective as other therapies for the treatment of osteoporosis 
(Epocrates, 2017). For these reasons, calcitonin is no longer commonly used in the treatment of 
osteoporosis. 
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Denosumab (Prolia) decreases bone resorption by inhibiting the activity of osteoclasts 
reducing bone resorption and turnover (Epocrates, 2017). Denosumab is indicated for increasing 
bone mass in men and post-menopausal women with osteoporosis. In particular, denosumab is 
indicated in those who have a high FRAX score, previous fragility fracture, multiple risk factors 
for fracture, those who are intolerant to other therapies, or who have failed other therapies. 
Denosumab is dosed subcutaneously every six months in the upper arm, upper thigh, or 
abdomen. Denosumab also can be used in those with renal insufficiency (Bethel et al., 2017). 
Treatment Modality and Role in Adherence to Therapy 
The type of treatment modality used for osteoporosis management plays a large role in 
patient adherence. One study by Durden et al. (2017), found that patients initiated with injectable 
therapy (34 - 41%) had greater persistence and adherence in a two-year period than those 
initiated with oral agents (20 - 31%). Patients who were receiving every 6-month injections had a 
statistically significantly higher adherence than those who were dosed more frequently, such as 
daily or weekly, whether it was oral or injectable agents. The study demonstrates the willingness 
of patients to adhere to treatment modalities that are less intrusive to their daily lives. The study 
also exhibits that patients feel a sense of accountability going to the clinic to receive injections 
that can increase compliance. Unfortunately, many of the treatment modalities that are dosed less 
frequently are more expensive. However, as more of injectable therapies become generic in the 
years to come they will be much more of a consideration (Durden et al., 2017). 
Cost of therapy is another contributing factor why patients are not adherent to 
osteoporosis therapy. The most common therapy choice for osteoporosis is oral bisphosphonates. 
The main reason for the preference is that they are the most effective and best-tolerated therapy 
available in generic form, ultimately decreasing the cost. Also, as mentioned previously, many 
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insurance companies require that a patient fail these medications or have a medical reason not to 
utilize them prior to covering the more expensive therapies. Teriparatide and denosumab are 
becoming preferred treatment options for many patients and providers, however, the cost remains 
prohibitive. Teriparatide costs on average $2,855.87 for a 4-week supply and denosumab costs 
$1,132.96 on average every 6 months (GoodRx, 2017). Patients may be unwilling to pay these 
prices and reluctant to receive therapy. The biggest issue is for those on Medicare Part D who 
have met their limit for the year and find themselves in the “donut hole,” in which they must pay 
for prescriptions out of pocket. Prior authorizations can be done to attempt to improve insurance 
coverage of these therapies, however, prior authorizations can be very time consuming and 
burdensome to providers. (LaVallee et al., 2016). Other conditions that immediately impact their 
health and quality of life may take priority in those situations. 
Osteoporosis is a disease that can adversely affect patients’ quality of life and increase 
mortality due to fragility fractures. Many issues remain for the treatment of osteoporosis to 
prevent these fractures. Increased awareness of these issues and improved confidence among 
primary care providers in the screening and management of osteoporosis can greatly impact the 
burden of osteoporosis for patients. 
Osteoporosis Quality Indicators 
The quality of osteoporosis management can be largely assessed by DXA screening rates 
at baseline for women >65 and DXA screening for those at-risk within 6 months of a fragility 
fracture (Cadarette et. al, 2010). Also included in osteoporosis quality assessments are the 
following: Treatment rates for those that meet diagnostic criteria for osteoporosis (T-score  -
2.5), those who have sustained a fragility fracture, and osteopenia patients who have high 
fracture risk based on the FRAX assessment tool (National Guideline Clearinghouse, 2013). To 
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assess quality of diagnosis and treatment of osteoporosis, the National Committee for Quality 
Assurance (NCQA) started tracking bone density measuring rates for women 65-85 on Medicare 
ever receiving a DXA scan. Most recently, in 2016 the rate for Health Maintenance Organization 
(HMO) Medicare was 73.8% and Preferred Provider Organization (PPO) Medicare was 79.3%. 
The NCQA also tracks osteoporosis management in women who have had a fracture. Testing 
and treatment of osteoporosis post-fracture is an in need of vast improvement in the field. Most 
recently, in 2016, the rate for HMO Medicare was 41.9% and PPO Medicare was 34.2%. The 
rates of baseline screening and post-fracture screening and treatment have significantly improved 
since initiation of these quality indicators, however, there is still need for improvement in both 
areas (NCQA, 2017). 
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CHAPTER FOUR. DESIGN AND IMPLEMENTATION 
Initial Patient Population 
In order to determine whether a project regarding osteoporosis treatment would be 
valuable, an initial EMR review was conducted by the office manager at the internal medicine 
clinic. The purpose of the review was based upon the impression of providers that patients with 
osteoporosis and treatment indications were not on sufficient pharmacologic therapy. A search of 
clinic patients who have had DXA scans was conducted for those that met the treatment 
guidelines of greater than or equal to 3% hip fracture risk or greater than or equal to 20% total 
fracture risk. The search was further narrowed down to those on treatment for osteoporosis and 
those who are not. The search revealed that of the internal medicine clinic’s 286 patients who 
met the above criteria, only 137 (47.9%) patients were on treatment for osteoporosis. See figure 
2 for depiction of these results.  
 
Figure 2. Internal medicine clinic patients with significant fracture risk treatment status for 
osteoporosis. 
 
48%
52%
Internal Medicine Clinic's Patients with High Fracture Risk 
Treatment Status
On treatment Not on treatment
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Methods 
To further evaluate these findings, a retrospective data analysis was performed. Chart 
reviews were completed to attempt to identify the reasons most of the internal medicine clinic’s 
patients with significant fracture risk are not receiving therapy for osteoporosis. EMRs were 
utilized in order to perform retrospective chart reviews. 
Sample 
The sample for these chart reviews was determined by an initial EMR review conducted 
by the clinic manager at the internal medicine clinic. It consisted of 149 patients at an internal 
medicine clinic in a Midwestern community with high fracture risk (≥ 3% hip fracture and/or ≥ 
20% overall fracture risk) based on their most recent DXA scan that were not on pharmacologic 
therapy. The number of charts that needed to be reviewed to get an accurate sample for the whole 
population was determined by Don Dillman’s Mail and Internet Surveys, the Tailored Design 
Method (2000). Based on the method, to get an accurate sample size of 149 charts (the number of 
patients not on treatment), 106 charts needed to be reviewed. The sample was selected via 
random sampling. One hundred and six charts provided an effect size of 50 - 50, 5% sampling 
error, and a 95% confidence interval. 
Data Collection 
The clinic has used the Centricity EHR system for eight years, which was the period that 
was reviewed as part of the retrospective chart review. Retrospective data prior to the 
implementation of the EHR system was not evaluated. Random sampling was achieved by 
putting all patient medical record numbers in numerical order and then reviewing every third 
chart in that order. In total, seven different providers’ patients were included in the sample. No 
data was collected regarding how many patients per provider as it was considered identifiable 
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information. It can be assumed that no one provider was overrepresented in the sample, as each 
provider had approximately equal distribution of patients included.  
Certain information was collected during the chart review process. Basic demographic 
data and FRAX criteria were collected. The demographic data included age, gender, height, 
weight, previous fracture, parental hip fractures, smoking status, glucocorticoid use, rheumatoid 
arthritis history, secondary osteoporosis status, alcohol usage, and femoral neck BMD (Centre 
for Metabolic Bone Diseases, 2017). Other data collected included which medications, if any, the 
patient had previously been on for osteoporosis, length of previous therapy for osteoporosis, 
insurance status, date of most recent DXA scan, and fracture risk and T-score from that scan. 
The reasons for patients not being on pharmacologic therapy for osteoporosis was separated into 
the following categories: 1) cost, 2) perceived lack of efficacy, 3) preference for “natural” 
treatment, 4) not clinically appropriate, 5) patient preference, 6) experienced side effects, 7) 
switch to alternate therapy, 8) drug holiday without restart, 9) lack of provider/patient follow up, 
10) provider recommended calcium and Vitamin D treatment, 11) patient concern over side 
effects, 12) no recent annual exam, and 13) no recent DXA scan. Additionally, data was 
collected regarding whether or not the patient was offered pharmacologic therapy per 
documentation in the EMR. 
Two interviews were conducted with healthcare provider key informants at the clinic to 
further evaluate the provider perspective on the issue. The first interview was with the key 
stakeholder physician who is an osteoporosis advocate within the clinic and the second informant 
was a physician assistant who specializes in women’s health in the same clinic. The interviews 
lasted approximately 15 minutes each. The questions asked during the interview process can be 
viewed in Appendix A. 
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Evidence-Based Intervention 
A meeting for the internal medicine clinic’s providers to attend was hosted. The results of 
the retrospective chart reviews and key informant interviews were presented at the meeting. 
Based on the results, a list of recommendations for improvement of treatment rates for patients 
with significant fracture risk was presented at the meeting. Adequate time for questions and 
discussion was provided. Not all the providers were able to attend the meeting, so an email was 
also sent following the meeting including the results of the EMR reviews and interviews with 
recommendations for improvement as well as topics that were discussed and relevant questions 
addressed at the meeting. After the presentation, an EMR change was implemented in order to 
improve documentation of non-treatment reasons and improve treatment rates of patients with 
significant fracture risk. The change is encountered when providers enter “Osteoporosis” or 
“Osteopenia” in the assessment section of patient visit notes. Once the diagnosis is selected, a 
patients’ most recent DXA information is auto-populated into the note, a patient’s current 
osteoporosis treatment plan is also populated and a pop-up window for the provider to select a 
patient’s treatment status and reasons for non-treatment. The provider then chooses the 
appropriate response for the situation and the data is populated into the note. 
Timeline of Project Phases 
Chart reviews were completed in August-September 2017. Key informant interviews 
were completed in January 2018. Statistical analysis of results was completed in January 2018. 
The written dissertation was completed in February 2018. Dissemination to providers was 
completed in March 2018. Defense of the dissertation was completed in March 2018. 
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Resources 
The main resource that was utilized for the project was the internal medicine clinic’s 
EMR system. The system utilized is Centricity. The office manager provided EMR access for the 
researcher could complete the retrospective chart reviews. Access to providers at the clinic was 
also necessary for key informant interviews and dissemination of results. No budget was 
necessary for the project. 
Logic Model 
 
Figure 3. A logic model representing the evaluation plan. 
 
Evaluation of Objectives 
Objective One: Complete a retrospective chart analysis to determine gaps, barriers, and 
successes related to osteoporosis management at an internal medicine clinic in a Midwestern 
community. Demographic data, FRAX criteria, and DXA scan results were collected along with 
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details regarding previous pharmacologic therapy used and reasons for no treatment or 
discontinuation of therapy. 
Objective Two: Conduct key informant interviews with clinic personnel to supplement 
chart analysis findings regarding osteoporosis management. Key informants included two 
providers at the internal medicine clinic and lasted approximately 15 minutes each. See 
Appendix A for questions asked during key informant interviews. Findings were written up in a 
question and answer format and evaluated for themes and differences. 
Objective Three: Provide recommendations for improvement of osteoporosis 
management based upon retrospective chart analysis and key informant interviews. 
Recommendations for improvement were given to providers at the internal medicine clinic 
during the dissemination of results meeting. Feedback was asked of providers on practicality of 
recommendations and discussion encouraged. Evaluation was achieved utilizing the 
Dissemination Evaluation form that can be found in Appendix D. 
Objective Four: Disseminate the findings of chart reviews and key informant interviews 
to providers at the internal medicine clinic. The dissemination process occurred in a 30-minute 
meeting with providers from the internal medicine clinic as well as be sent out via email form for 
providers unable to attend. 
Objective Five: Implement an EMR change in order to improve documentation of non-
treatment reasons and/or improve the proportion of patients receiving treatment. Feedback from 
providers was asked at the dissemination meeting regarding the change and perceived benefit. 
Protection of Human Subjects 
The participants in the project included 286 internal medicine clinic patients who had 
significant fracture risk. These participants were not directly involved in person for any portion 
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of the project. The project consisted of chart reviews, interviewing healthcare provider key 
informants, disseminations of results, and recommendations for improvement. The biggest risk to 
participants in the project was confidentiality since private health information was reviewed. 
There was no recruitment of subjects for the project. Since the project consisted of 
retrospective chart reviews of existing data with minimal risk to subjects, informed consent was 
waived. The research did not adversely affect the rights or welfare of participants involved. Risk 
to participants was minimized by the Health Insurance Portability and Accountability Act 
(HIPAA) of 1996 Privacy Rule. The researcher received formal training under the act and 
operated under the constraints of the rule. No identifiable private health information was utilized 
for the purposes of the project and no HIPAA violations were encountered during any portion of 
the practice improvement project. 
The purpose of the project was to examine and bring awareness of the lack of 
pharmacologic therapy in patients with significant fracture risk to providers at the internal 
medicine clinic as well as implement an EMR change to improve documentation of treatment 
decisions. The goal was that with the increased awareness and EMR change, providers would 
changes to their practice based on recommendations suggested. If the percentage of patients with 
significant fracture risk on pharmacologic therapy increases, there may be fewer fragility 
fractures, which should increase quality of life and decrease mortality among the population. 
Since osteoporosis is a disease found more frequently in women, they were included in 
the project. Minorities were also included in the project sample; however, race and ethnic data 
were not collected for any portion of the project. Since the project only involves chart reviews, 
interviews with healthcare provider key informants, dissemination of results, and 
recommendations for change the risk to women and minorities was minimal. Since the internal 
 25 
medicine clinic utilized for the project specializes in providing internal medicine services for the 
adult patient, there were no children included in the project. 
Approval for protocol #PH17267 was received on July 27, 2017 from the North Dakota 
State University Institutional Review Board. The approval letter can be found in Appendix C. 
The project fell under the expedited review category for North Dakota State University. 
Disclosure of Relationships 
The researcher involved in this project had vested interest in the clinic involved. Upon 
completion of her graduate degree, she will be working in the clinic where the project took place. 
The key stakeholder physician involved in this project is the researcher’s father. Because a 
retrospective review of EHR data was the primary point of interest for the study, it is unlikely 
that this relationship influenced the results. The key stakeholder physician owns a 
pharmaceutical research company which researches medications utilized in the treatment of 
osteoporosis. Although, it is unlikely that many of these research participants were included in 
this study, it is possible and could influence the results. The key stakeholder physician is 
perceived as a local expert in the field of osteoporosis management for the community in which 
the project took place. He has over 35 years of experience in the diagnosis and treatment of 
osteoporosis. With this expertise in mind, it was felt to be valuable for the physician to serve as a 
key informant for the project. All of these factors could have played a role in the perception of 
this practice improvement project and therefore must be disclosed. 
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CHAPTER FIVE. RESULTS 
Sample 
The sample for the project was pre-determined by the internal medicine clinic’s initial 
chart query. The initial population data can be seen in the project design section of the paper. 
The total sample population was 286 patients with increased fracture risk (total fracture risk of ≥ 
20% or hip fracture risk of ≥ 3%). Since the project was focused on identifying reasons patients 
are not receiving pharmacologic therapy, chart reviews were limited to those not currently on 
treatment. Based on Don Dillman’s Mail and Internet Surveys, the Tailored Design Method, to 
get accurate data in a sample size of 149, 106 charts were reviewed (2000). One hundred and six 
charts provided an effect size of 50 - 50, 5% sampling error, and a 95% confidence interval. 
Random sampling was utilized in order to decide which charts were to be reviewed. Table 1 
provides a breakdown of the basic demographic data collected from retrospective chart reviews 
of the population. 
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Table 1 
Demographic data for retrospective chart reviews 
Total (N) 286 
Total on pharmacologic therapy 137 (47.9%) 
Total not on pharmacologic therapy 149 (52.1%) 
Distribution male vs. female Male – 12 (8.1%) 
Female – 137 (91.9%) 
Age 78.04 x̅ 
Range 57 - 92 
7.88 s 
Insurance Provider Medicare – 101 (95.3%) 
Private Insurance – 3 (2.8%) 
Medicaid – 1 (0.9%) 
Body Mass Index 26.90 x̅ 
Range 16.37 – 44.40 
5.12 s 
 
Retrospective Chart Review Results 
Each chart was reviewed and most recent DXA scan results were collected including 
Femoral Neck BMD, T-score, and FRAX scores. Table 2 provides a breakdown of the average 
scores for the sample of charts reviewed. 
Table 2 
DXA scan distribution results for sample of patients reviewed 
DXA Result Component Average Range Standard Deviation 
Femoral Neck BMD 0.73 g/cm2 0.48 g/cm2 - 0.892 
g/cm2 
0.08 g/cm2 
Femoral Neck T-score -2.2 (-1.0) – (-3.4) 0.53 
Overall Fracture Risk 18.37% 8.20% - 37.50% 0.06 
Hip Fracture Risk 5.69% 2.60% - 27.30% 0.04 
 
In order to understand the data more fully, the patient distribution of osteopenia diagnosis 
versus osteoporosis diagnosis can be viewed in Figure 4. Seventy-two percent of patients were 
diagnosed with osteopenia and 28% with osteoporosis based on T-score values. 
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Figure 4. Sample distribution comparison of patients with osteopenia vs. osteoporosis based on 
T-score 
 
FRAX criteria were collected during chart reviews including, previous fracture, smoking 
status, parental hip fracture, secondary osteoporosis, glucocorticoid use, rheumatoid arthritis 
history and alcohol use. FRAX criteria information can be located in Tables 3 and 4. 
Table 3 
Other FRAX criteria of patient sample 
Variable 
N=106 
Yes No 
 n Percentage n Percentage 
Previous Fracture? 35 33.02% 71 66.98% 
Parental Hip 
Fracture? 
6 5.66% 100 94.34% 
Glucocorticoid Use 6 5.66% 100 94.34% 
Rheumatoid Arthritis 
History 
4 3.77% 102 96.23% 
Alcohol (≥ 3 U/day) 1 0.94% 105 99.06% 
 
 
 
 
 
Distribution of Osteopenia vs. Osteoporosis
Osteopenia Osteoporosis
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Table 4 
Smoking Status of patient sample 
Never Current Former 
N=106 
n Percentage n Percentage n Percentage 
77 72.64% 6 5.66% 23 21.70% 
 
During chart reviews, information was collected regarding medications patients have 
utilized previously for osteoporosis treatment. The average number of medications previously 
used for the sample was 0.519 with a range of 0-4 and a standard deviation of 0.831. Many 
patients in the sample studied had never utilized treatment previously so that is why the average 
is less than 1. To further evaluate these findings each individual medication patients had utilized 
previously was listed and the distribution of different medications utilized previously in the 
population can be seen in Figure 5. In addition, the length of each medication use was collected, 
and the mean was calculated for the population as a whole. The data is depicted in Figure 6. 
 
 
Figure 5. Previous medications used for patients with high fracture risk not currently on 
pharmacologic therapy obtained from retrospective chart reviews. 
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Figure 6. Average duration of previous pharmacologic therapy for patients with high fracture 
risk not currently receiving treatment obtained from retrospective chart reviews. 
 
Possible reasons for patients not being on pharmacologic treatment for their elevated 
fracture risk was gathered from retrospective chart reviews. Most of the information was 
gathered from progress notes, phone notes, previous medications used, and results letters. Not all 
information was easily found via chart reviews. The depiction of these results can be viewed in 
Figure 7. 
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Figure 7. Reasons for discontinuation or no treatment gathered from retrospective chart 
reviews. 
 
Based on information gathered during the chart reviews, whether or not patients were 
offered pharmacologic treatment based on their fracture risk score was collected. The 
information came from progress notes, results letters, and whether patients had previously been 
on therapy or not. The depiction of these results can be seen in Figure 8. 
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Figure 8. Representation of patients with high fracture risk not currently receiving therapy of 
whether or not they were offered pharmacologic therapy obtained from retrospective chart 
reviews. 
 
In order to further analyze these findings, characteristics from each group were gathered. 
See table 5 in order to view the average age, overall fracture risk, and hip fracture risk for the 
patients offered pharmacologic therapy and the patients not offered pharmacologic therapy to 
decrease their fracture risk. 
Table 5 
Breakdown of patients not offered and offered pharmacologic therapy average age along with 
fracture risk scores 
Not Offered Pharmacologic Therapy Offered Pharmacologic Therapy 
Average Age Average 
Overall 
FRAX Score 
Average Hip 
FRAX Score 
Average Age Average 
Overall 
FRAX Score 
Average Hip 
FRAX Score 
79.4 15.18% 4.04% 77.655 19.03% 6.05% 
 
A comparison was made regarding whether patients had received previous pharmacologic 
therapy or not and their T-score values and FRAX scores. These results can be viewed in Table 
6. 
Offered Pharmacologic Treatment
Yes No
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Table 6 
T-score and FRAX score comparison between patients who have received previous 
pharmacologic therapy and patients who have not 
No Previous Pharmacologic Therapy Previous Pharmacologic Therapy 
Femoral 
Neck T-score 
Overall 
FRAX Score 
Hip FRAX 
Score 
Femoral 
Neck T-score 
Overall 
FRAX Score 
Hip FRAX 
Score 
-2.09 17.05% 4.95% -2.33 20.56% 6.96% 
 
Formal statistical analyses could have been utilized in order to more extensively evaluate 
the 106 patient charts in the population sample. However, with no valid null hypothesis, these 
results would have provided little to no additional benefit for the evaluation of these results. 
Upon the advice of a consulted biostatistician, more formal and extensive statistical analysis 
were not utilized in the results of the project. It was determined that descriptive statistics were a 
more appropriate method to use. 
Key Informant Interview Results 
Two interviews were conducted with providers at the clinic, one was an internal medicine 
physician with over 30 years of experience, and the other was a physician assistant with over 15 
years of experience. The interviews lasted around 15 minutes each. These providers see many 
elderly women in their practice, so most patients encountered were typical patients with elevated 
fracture risk and low BMD due to aging and estrogen depletion. However, it was estimated that 
about 5% of patients were “atypical” patients with low BMD due to secondary causes, such as 
long-term corticosteroid use or alcoholism. 
When interviewing providers regarding osteoporosis/osteopenia treatment based on 
fracture risk, it was clear that FRAX scores were crucial in treatment decisions. Both providers 
utilize FRAX scores in their decision-making in addition to femoral neck BMD for comparison 
to previous DXA scans and T-score values to diagnose osteopenia or osteoporosis. Both 
providers preferred to use denosumab first-line because it is easy to make sure that the patient is 
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actually taking the medication since they have to come to the clinic for injections. Some 
insurance companies require patients to have tried to use a bisphosphonate previously or have a 
medical reason why it is contraindicated to use bisphosphonate therapy. In these scenarios, 
usually alendronate is used first-line for these providers. The providers agreed that many patients 
would say that they are taking their osteoporosis medications when they are not actually taking 
them, which drives the preference for denosumab first-line. The key informant physician would 
like to use teriparatide more often; however, it is very difficult to get insurance companies to 
cover the medication. In addition to the medication component, approach to therapy also 
consisted of weight bearing exercise, calcium and Vitamin D supplementation. 
The most common reasons encountered by these providers for their patients being 
unwilling to use or stopping therapy are cost, concern over side effects, experienced side effects, 
or perceived lack of benefit. There are also factors out of their control that contribute to patients’ 
feelings about these medications including false information obtained from the internet or friends 
and family. Patients also frequently do not consider potential benefits from receiving therapy for 
their osteoporosis to prevent fractures. Providers at the clinic try to reassess patients’ willingness 
to utilize medication to treat their low BMD or elevated fracture risk at the next visit following 
the DXA scan, annual visits, or with repeat DXA scans. If patients are completely unwilling to 
use pharmacologic therapy and do not anticipate changing their mind, providers and patients may 
opt to not continue with DXA screening.  
Medical reasons that these providers may feel it is inappropriate to utilize pharmacologic 
therapy to decrease fracture risk include upcoming major dental work due to osteonecrosis of the 
jaw risk, however, it is usually only a consideration when the patient is on the injectable 
therapies and due for an upcoming injection. In those situations, the providers will hold their 
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injection for 3 months after the dental work is complete. Neither provider will typically hold any 
of the oral agents in relation to dental work. Other reasons include chronic kidney disease stage 
IV and patients on hemodialysis. However, these reasons are usually only issues with 
bisphosphonate therapy and do not apply to teriparatide or denosumab. 
A patient’s age is considered when starting or discontinuing therapy for these providers. 
Typically, when a patient is above 90, the decision to stop treatment is considered. It is very 
much considered by every unique patient situation. If a patient is a healthy, active 90 year old 
then discontinuing therapy would not be ideal. On the other hand, if a patient were older than 90 
and bedbound in a nursing home with many other comorbid conditions, then discontinuing 
treatment would be very likely. 
Dissemination Evaluation Results 
A meeting was held with providers at the internal medicine clinic to disseminate results 
of retrospective chart reviews and key informant interviews. The meeting lasted approximately 
15 minutes and five of the six main providers at the clinic were able to attend. The executive 
summary document in Appendix E was utilized for the dissemination meeting along with spoken 
description of the results by the researcher. Each of the providers filled out the dissemination 
evaluation form listed in Appendix D.  
All five providers said that the information presented at the meeting would influence their 
practice. Comments on this question included improvement of documentation of non-compliance 
reasons, changes to process for updating problem list, and improvement of patient education. The 
second question asked if the providers could identify a performance or quality gap that would 
improve treatment compliance of osteoporosis patients. All providers answered yes to this 
question as well. Comments included patient education, improving documentation, updating 
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problem list, updating medication list, and improvement in identifying high fracture risk patients. 
The last question of the dissemination evaluation form asked if the providers had any final 
comments regarding the topic. Four out of five providers said yes to this question. Comments 
included treatment of osteopenia is not well covered by insurance, DXA audit would be a good 
idea, good information to remember, helps with patient compliance, well-written, nice job, and 
useful information. The key informant physician, who is the researcher’s father, was present at 
the dissemination meeting. With this in mind, the results could have been influenced due to this 
relationship, so it must be disclosed. 
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CHAPTER SIX. DISCUSSION AND CONCLUSION 
Interpretation of Results 
The samples utilized for the study were individuals with increased fracture risk as defined 
previously. Specifically, targeted were those people who, according to the EMR system, were 
not currently receiving treatment to maintain their BMD. Not surprisingly, 91.9% of the sample 
was women, which is consistent with prevalence data since osteoporosis is most common among 
females. The average age of the sample was 78.04 with a range of 57-92. Osteopenia and 
osteoporosis are more common in the elderly population, so these ages were consistent with that 
fact. Also, 95.3% of the people in the study were covered via Medicare health insurance, which 
typically starts coverage at the age of 65. No one in the sample was uninsured. 
When the DXA scan results were broken down and analyzed, it was interesting to see that 
all of the patients in the sample had a T-score value of -1.0 of less, which puts them at least in 
the osteopenia range. To further analyze these results, 72% of the sample was diagnosed with 
osteopenia and 28% had osteoporosis based on their T-score values. Since the patients also had 
increased fracture risk, according to the National Guideline Clearinghouse “Diagnosis and 
Treatment of Osteoporosis” guidelines (2013) as well as the “Clinician’s Guideline for the 
Prevention and Treatment of Osteoporosis” (2014) all of the patients in the sample should be 
considered for treatment based upon the information listed above (Cosman et al, 2014). 
The average overall FRAX score was 18.37, which is less than the overall FRAX 
threshold of ≥ 20%. Only 29.25% of the patients in the sample met the overall FRAX score 
threshold. The guidelines still suggest that these patients are considered high risk for fractures 
and can be considered for pharmacology treatment due to the hip FRAX score elevation. 99.05% 
of the sample met the fracture risk criteria based on the hip FRAX threshold of ≥ 3%. Given this 
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information, the majority of patients in the sample had minimal elevation in their fracture risk. 
Providers may not have been as aggressive with treatment recommendations due to the minimal 
elevation and the majority of patients only meeting one and not both of the FRAX thresholds. 
Previous medications utilized by the sample of patients were analyzed in a variety of 
ways. As previously demonstrated, the majority of patients in the sample had never been on 
treatment to decrease their fracture risk. Alendronate and denosumab were the most common 
medications that patients had utilized previously, if they had been on therapy. However, the 
medication with the best adherence for length of treatment was zoledronic acid, which is an 
intravenous infusion given once yearly at 4.5 years followed by alendronate which was right 
under 3 years. All of the other therapies averaged around 1 year or less of total treatment time. 
With exception to zoledronic acid, these results contradict other studies that have been done 
regarding length of treatment via type of method. The previous studies have shown that the less 
frequently the medication has to be taken, the longer patients typically will take them (Durden et 
al., 2017). Zoledronic acid is only administered once per year and was used with the longest 
duration on average, one would expect that denosumab would be the next longest duration of use 
due to administration frequency of twice per year. In comparison, alendronate is administered 
once per week, but was second in average duration of use length. 
One patient in the sample had been on a research medication previously. The key 
stakeholder physician owns a research company that has done research on osteoporosis 
medications previously. Limited information was available about this research medication. It is 
unknown if the patient was on placebo or the active medication and what DXA requirements 
were part of the study, etc. There is a possibility that other patients in the sample were in 
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investigational studies for osteoporosis, although, this was not specifically documented via the 
chart reviews except on the one occasion.  
 Reasons for patients discontinuing or not ever being on treatment were the hardest part of 
the data to analyze. The main reason for the difficulty was lack of documentation for these 
reasons. When previous drugs were discontinued via the EMR system, the most common 
response was “Course Completed.” While course complete is true in a sense, there was likely 
more to the story regarding why patients stopped their treatment. If providers did not discuss the 
reason in their progress notes, then it was very hard to understand why these medications were 
stopped. While the commonly studied reasons of experiencing side effects, concern over possible 
side effects, cost, and preference for natural treatment were all encountered a handful of times 
with clear documentation, this was the exception and not the rule during these chart reviews. 
 The biggest factor identified for not starting or continuing pharmacologic treatment was 
that providers did not officially recommend that the patients start on pharmacologic therapy, and 
instead recommended that patients remain on their calcium and vitamin D supplement only. This 
type of recommendation was commonly encountered with patients whose fracture risk was 
mildly elevated. Often in these scenarios, providers would send results letters to these patients 
stating that since their fracture risk is mildly elevated they could consider treatment, however, it 
is also reasonable for them to remain on their calcium and vitamin D and recheck a DXA scan in 
2 years. In these situations, providers were not recommending treatment even though these 
patients had significant fracture risk and were at least in the osteopenia range. These 
recommendations by the providers are in contrast with guidelines that recommend patients 
should be considered for treatment if they have significant fracture risk because it is cost 
effective (Cosman et al, 2014) (National Guidelines Clearinghouse, 2013). 
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 Lack of provider or patient follow up was a large contributor for why many patients were 
potentially not on therapy. As stated above, many situations were encountered during the reviews 
of providers sending results letters to patients and stating that the patient’s fracture risk was 
elevated, and they would qualify for treatment to decrease fracture risk, however, staying on 
calcium and vitamin D and rechecking DXA scan in 2 years would also be a reasonable option. 
The letters often ended with statements similar to, “if you are interested in starting therapy please 
contact my office.” After these letters, osteoporosis or fracture risk was often not readdressed 
until the next annual visit or repeat DXA scan. In some situations, neither the patient or provider 
had followed up regarding the potential availability of treatment and the lack of follow up 
contributed to why the patient was not on therapy. Both parties bore some responsibility in order 
for follow up to occur. The patient was told to contact the office if they were interested, however, 
there was often a missing education component regarding why the therapy may be beneficial in 
the first place. If a patient is given a letter without mention of the potential benefits of starting a 
new prescription, the patient would likely choose conservative treatment. In many cases, patients 
stayed on calcium and vitamin D supplement and repeated the DXA at a later time since that is 
the most convenient option and they were not fully aware of the benefits of the aforementioned 
option. 
 As can be seen in the results, 82% of the sample patients were offered pharmacologic 
therapy to decrease their fracture risk. However, as stated previously, many times they were 
offered therapy but also told that it was reasonable to stay on calcium and vitamin D and recheck 
a DXA in 2 years. Ambiguous messages can be confusing to patients since they were not likely 
educated regarding potential benefits of starting therapy for their mildly elevated fracture risk. 
Also included in the percentage were patients who had previously been on therapy, since at one 
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point they were offered and accepted therapy for the condition. Given the background 
information, the fact that 82% were offered therapy is somewhat misleading. To gain further 
insight into the data, the mean age and fracture risk scores were evaluated for patients who were 
previously offered therapy and those who were not. The patients offered therapy were, on 
average, younger and had higher fracture risk percentages than those who were not. The data is 
rather intuitive because patients who were younger at the onset of osteopenia or osteoporosis 
have more time for future risk of fractures and likely less other co-morbid conditions that would 
contraindicate therapy. Also, the patients that were offered therapy had higher fracture risk on 
average, making providers more aggressive with their treatment recommendations. 
 To further analyze offering pharmacologic therapy to patients, data was compared 
concerning patients who had been on pharmacologic therapy previously and those who had not. 
T-scores for patients who had never been on therapy were higher than those who had been 
previously treated. FRAX scores were higher for the patients who had received previous therapy. 
Again, the data was rather predictable because patients whose T-scores and fracture risk were 
higher would make providers more aggressive with their treatment recommendations and these 
patients were more likely to be on therapy previously. 
 Other potential reasons commonly encountered were regarding frequency of annual 
exams and follow up DXA scans. “No recent annual exam” or “No recent DXA scan” were 
marked as potential contributing reasons for no treatment when an annual exam was not done in 
the last 3 years or a DXA scan was not repeated since 2013 or before. The reasons why some of 
the patients were not having annual exams is not fully clear, though there are some patients at the 
clinic that come for more specialized care and not for primary care. The researcher excluded 
these patients from the sample whenever that situation was clear, however, it is possible that a 
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few remained in the sample despite efforts to remove them. Since osteoporosis is typically a 
“silent” disease until a fracture occurs, sometimes the only time it gets addressed for patients is 
at annual exams when discussing preventative health services, such as DXA scans. Since DXA 
scans are essential for evaluation of treatment, if a patient had not had an annual exam in the last 
3 years it was counted as a potential contributor for why a patient was not receiving treatment. 
On the same note, if a patient had not had a recent DXA scan it was more likely that they were 
not on treatment because there was no reminder to address the condition. It is possible that due to 
patient age or previous denial of treatment, the patient’s provider or the patient themselves have 
deemed it unnecessary to continue checking BMD levels, however, these reasons were not 
obvious from the chart reviews. 
 Overall, the healthcare provider key informant interviews aligned with data obtained 
from chart reviews. One contradiction was regarding follow up for reassessment of therapy. 
While the providers were optimistic in their opinion that treatment decisions reassessment would 
ideally get addressed at the next visit, data from chart reviews contradicted that information. 
Their opinions regarding barriers to therapy and patients’ reasoning for stopping or never starting 
therapy were consistent with information found in chart reviews. 
 Overall, the dissemination evaluation had a positive response from providers. They were 
very accepting of the EMR change to improve documentation of non-treatment reasons. Also, 
the providers found an easy solution to solving the issue with osteopenia or osteoporosis not 
being in the patient’s problem list. The DXA scan technician now has an added duty of inputting 
the appropriate diagnosis based on the DXA results at the time of the scan. The nurses will also 
be educated to ensure that injections given for osteopenia or osteoporosis is listed on the patient 
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medication list at the time of the injection encounters. Providers also acknowledged a need to 
input the medication on the patient’s list at the time of ordering.  
 There were some less positive findings that emerged during the dissemination. Providers 
are hesitant to spend any additional time on patient education regarding treatment to reduce 
fracture risk, due to the many medical conditions that are being treated at any given visit. Also, 
the office manager and providers stated that treatment for patients with osteopenia and high 
fracture risk is not very well covered by insurance companies. 
Limitations 
Several limitations must be considered when evaluating the results of the practice 
improvement project. The project was conducted at an independent internal medicine clinic in 
the Midwest. Quality measures that exist at larger organizations are not formally in place at the 
clinic or at most independent facilities. Each provider had a different approach to how they 
treated and educated patients about DXA scan results and osteoporosis treatment. In addition, 
since internal medicine is the specialty of focus within the clinic, many of the patients are of 
advanced age and have complex medical backgrounds. With the individuality in mind, the results 
are not transferrable to other clinics, even small independent clinics.  
Another consideration is the population used for the project. Since the clinic is internal 
medicine in focus, most patients who receive care there are also primary care patients of the 
clinic. However, some patients seek care at the clinic for more specialized care of certain 
conditions, such as diabetes mellitus type II, and have a primary care provider elsewhere. The 
issue arose a few times during retrospective chart reviews. Even though the patient had a 
separate primary care provider, they had a DXA scan at the clinic being studied and appeared in 
the sample size because there was not a DXA scanner available at the other clinic. Whenever the 
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researcher saw what appeared to be this type of situation, the patients were excluded from the 
sample, however, it is possible that some remained in the sample despite efforts to remove them. 
One more limiting factor to consider, is that the researcher only evaluated the patients 
who were not currently receiving pharmacologic therapy for their fracture risk. The results might 
have been much different if all patients with significant fracture risk were included in the sample. 
The patients included in the sample could have been more resistant to receiving therapy in the 
first place since they were not currently receiving anything, which could have skewed the results 
a certain way. 
The biggest limiting factor of the research was the ability of the researcher to find 
information in the EMRs. The specific reason(s) for patients not being on treatment was the 
hardest to find. All medications that were previously discontinued for osteoporosis management 
were viewed and the reason for discontinuation was evaluated. Despite an embedded EMR 
feature prompting the reason for medication discontinuation, little valuable information was 
found in this area. Occasionally, nursing or the provider would write reasons for discontinuation 
in this section which made the information very easy to find. The most common reason for 
discontinuation identified was “course complete”, which is likely the default response when 
discontinuing any medication.  
Another limitation which was originally mentioned by the key stakeholder physician 
involved in the project is that patients often tell you that they are taking these medications for 
osteoporosis when in reality they may not be taking them. There is no way to verify that patients 
are being honest, so the results of the chart review are based upon the fact that the patients who 
are documented as being on therapy are actually taking the medication. Also, the results of the 
project relied on a thorough medication review of the nursing staff and providers in order to 
 45 
assure medication lists are up to date with what the patients are currently taking. The up to date 
medication reviews also assumes that the patient is knowledgeable in what they are taking when 
these reviews are happening. With all of these considerations in mind, it is possible that in an 
ideal world with perfect charting, these results would have been much different. 
Recommendations 
The first recommendation which was implemented at the conclusion of the project was an 
update to the EMR system to improve documentation of treatment decisions for patients with 
significant fracture risk with the goal of improving treatment rates of these patients within the 
clinic. A change was incorporated into the system when providers enter osteoporosis (ICD-10: 
M80-81) or osteopenia (ICD-10 M85.8) diagnosis codes in the assessment section of their clinic 
visit notes. The template for these diagnosis codes already fills in the most recent DXA scan 
information including fracture risk, however, a new area was added to ask providers why patients 
with significant fracture risk are not receiving pharmacologic therapy. 
A second recommendation to the clinic involved putting osteoporosis or osteopenia into 
patients’ problem lists. During the retrospective chart reviews, the author found nine different 
patients whose DXA scan report showed either osteoporosis or osteopenia and the diagnosis was 
not listed in the active problem list. These lists are crucial to have up to date in the clinic setting. 
At a patients’ annual visit, the provider often looks at these lists and makes sure to cover each of 
them if possible at the visit. If the patient does have osteoporosis or osteopenia and the diagnosis 
is not included in the problem list, it is likely not going to get as much focus at annual visits, 
which is usually the only time osteoporosis gets discussed. Because it is a silent disease, a patient 
will not usually come into the clinic with a complaint of osteoporosis unless they have sustained 
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a fracture. Also, osteoporosis often gets discussed at annual visits because as part of preventative 
healthcare, DXA scans are usually only ordered or recommended at annual visits. 
A third recommendation was also based on findings from the retrospective chart reviews. 
The original sample was based on patients’ medication lists and whether or not they were 
receiving therapy for osteoporosis. It was noted during the reviews in eleven separate instances 
that patients were included in the non-treatment sample, however, once the review started they 
were found to have received an injection of denosumab in the previous 6 months. These patients 
were subsequently moved to the treatment portion of the sample. The recommendation to the 
clinic involved ensuring that patients’ medication lists are up to date, even if they are only 
receiving these injections every 6 months and not taking a medicine daily. It is important not 
only as the primary care provider to be aware that your patient is receiving these injections, but 
to every other provider who may take care of the patient during the half lives of the medication 
in order to evaluate for drug interactions. When nursing staff is administering these medications 
in the clinic, they should be double checking that the medication is present on the patients’ list 
each time.  
Lastly, while it was not always clear from documentation why patients were not receiving 
treatment for their osteoporosis or significant fracture risk, the common reasons for patients 
stopping or refusing therapy were definitely found in the review. Patient education is something 
that can always be improved. It was suggested by the key stakeholder physician for the project to 
have an osteoporosis champion, of sorts, within the clinic. The provider would serve as patient 
educator for those with significant fracture risk who should be receiving pharmacologic therapy 
and are resistant to the recommendation. The goal of the intervention would be to avoid fragility 
fractures and associated morbidity and mortality by increasing or maintaining a patient’s BMD 
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level. The ideal patients for the provider to see would be those who are resistant due to lack of 
information, knowledge of the disease process, or who have received false information. The 
designated osteoporosis education provider is something that the clinic was very interested in 
pursuing in the future. 
Implications for Practice 
Retrospective chart reviews demonstrate the importance of up-to-date and accurate 
medication and problem lists for our patients. The chart reviews proved to be more difficult than 
originally anticipated due to lack of documentation for discontinuation reasons, as well as 
medication lists that did not accurately reflect what patients are taking. In a busy clinic life, it is 
easy to see how some of these minor issues with charting and medication reconciliation can fall 
prey to other day to day activities. Despite the competing priorities of primary care, out of date 
records can vastly impact treatment decisions. 
In addition to the recommendations made above, the FRAX tool has much more value 
than just assessing for fracture risk with a BMD measurement. FRAX can be utilized with or 
without the BMD information. Providers can start calculating the measurement on high risk men 
and women far before they have their first DXA scan. According to the International 
Osteoporosis Foundation, postmenopausal women ages 50-64 should be considered for a DXA 
scan if they have a total osteoporotic fracture FRAX score of ≥ 9.3%. Many women and men in 
this age group are likely not having their FRAX score calculated, thus missing some high-risk 
individuals who may benefit from earlier intervention to prevent fragility fractures. Primary care 
could help their patients a great deal by incorporating FRAX into their practice at earlier stages. 
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Implications for Future Research 
To further evaluate the results of the project, another study would need to be done. The 
study would involve the total sample size of patients with high fracture risk, including those that 
are currently on pharmacologic therapy according to the EMR system. Broadening the sample 
for the project would give a more in-depth picture as to why patients discontinued previous 
agents and how long they have been on the current modality they are using. Also, in future 
studies more attention could be focused on specific medications and the reasons associated with 
each one for discontinuation 
Any future studies would be conducted after the EMR system improvement was 
implemented and the recommendations for improvement were presented to the providers and 
staff. The changes would allow better documentation regarding reasons for declining or 
discontinuing certain agents to retrieve better quality data. Having a follow up study after the 
EMR change had taken place would also help to evaluate if the EMR system reminder for 
patients with high fracture risk actually improved treatment rates and documentation processes in 
the clinic. 
Expanding the topic to larger health systems in the area who may have different quality 
measures in place would be interesting to compare to smaller independent organizations. 
Ultimately, comparing different areas of the United States regarding adherence to treatment and 
fracture risk would provide a lot of insight into the topic, although that is out of the scope of the 
project. 
The key stakeholder physician involved in the project from the beginning has decades of 
experience working with patients with osteoporosis. In his hospital experience, he noticed a large 
area of need for patients to be worked up for osteopenia or osteoporosis and potentially started 
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on treatment following fragility fractures by their primary care providers. He noticed that the 
diagnostic work-up post fragility fracture is an area that is missed often and recommended the 
idea for a practice improvement project initially. A different project focus was chosen due to the 
complexity of working with several different organizations. However, much research has been 
done on the topic area and a need for improvement has been demonstrated. Further examination 
regarding why patients may be missed during transition of care from hospital or emergency room 
follow-ups could be a great area for practice improvement in relation to osteopenia and 
osteoporosis management. Individuals should be worked up for osteoporosis and potentially 
started on treatment in order to reduce the risk of future, potentially devastating fractures 
following discharge from the hospital or ED after a fragility fracture. 
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APPENDIX A. KEY INFORMANT INTERVIEW QUESTIONS 
• For typical osteoporosis patients with significant fracture risk- what is your approach 
to therapy? 
o How many truly atypical patients do you see per year? 
• What are your most commonly used types of pharmacologic treatment for 
osteoporosis? 
• What are the most common reasons that you see in patients who are unwilling to use 
pharmacologic therapy to treat their osteoporosis? 
• What barriers to optimal therapy do you commonly encounter in practice? 
• What are some reasons that you as a provider would not clinically recommend for a 
patient with high fracture risk to utilize pharmacologic treatment? 
• What portion of DXA scan results do you use in your treatment decisions? 
• How often do you reassess patients’ willingness to use pharmacologic therapy for 
osteoporosis? 
• What factors out of your control impact how you care for and treat a patient with 
osteoporosis and high fracture risk? 
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APPENDIX D. DISSEMINATION EVALATION TOOL 
 
 
Title: Osteoporosis- Dissemination of Retrospective Chart Reviews / Interview Results 
Presenter: Karissa Emerson, DNP-S 
Date: 
 
Will the information presented today influence your practice in any way?          Yes          No 
 If yes, please explain:___________________________________________________________________ 
_____________________________________________________________________________________  
_____________________________________________________________________________________  
_____________________________________________________________________________________  
Is there a performance or quality gap that you can identify that would improve the treatment compliance 
of osteoporosis patients?                                                                               Yes          No 
If yes, please explain:___________________________________________________________________ 
_____________________________________________________________________________________  
_____________________________________________________________________________________ 
_____________________________________________________________________________________  
Do you have any final comments regarding the topic?                                            Yes          No 
If yes, please explain:___________________________________________________________________ 
_____________________________________________________________________________________  
_____________________________________________________________________________________  
_____________________________________________________________________________________  
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APPENDIX E. EXECUTIVE SUMMARY FOR DISSEMINATION TO CLINIC 
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APPENDIX F. EXECUTIVE SUMMARY 
Background and Significance 
Osteoporosis is a condition that decreases the density of bones resulting in weaker bones 
and greater risk of fragility fractures. Fragility fractures occur with less force than may be 
expected in the fracture of a normal bone, usually including falls from standing height or less. 
Risk factors for the development of osteoporosis include aging, estrogen deficiency, low calcium 
and vitamin D intake, and certain disorders Prevention of fragility fractures related to 
osteoporosis is imperative because they can devastate the lives of patients. Patients may lose 
independent functioning, have chronic pain, or even die as a result of these fractures. Fragility 
fractures increase costs for hospital and surgical care and indirectly result in loss of productivity 
for patients with loss of independence and need of nursing home or institutional care. 
Osteoporosis and subsequent fractures can be prevented with adequate calcium and vitamin D 
intake, weight bearing exercise, and pharmacologic therapy. 
Many patients think of osteoporosis as a “silent disease” and do not see the benefit in 
receiving medication for primary fragility fracture prevention. Adherence to pharmacologic 
therapy remains the largest issue with treatment for providers. Historically, osteoporosis 
treatment decisions were based off T-score values alone, however, it has been realized in more 
recent years that T-score values are not the optimal way to measure fracture risk, because many 
fragility fractures occur in people outside the T-score ranges, most occurring within the 
osteopenic range.  
Osteoporosis is the cause of more than 8.9 million fractures annually which equates to 
one fracture every 3 seconds. One out of three women over the age of 50 will experience an 
osteoporotic fracture as well as one out of five men the same age. A critical aspect of 
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osteoporosis management is identifying and treating patients who are at the highest risk for 
fractures before they have sustained one. Successful osteoporosis management reduces the risk 
of first time fracture in 5 years from about 34% to 10%. Osteoporosis treatment to prevent 
fractures is a difficult task for many reasons, including cost, side effects, patient perception of 
efficacy and safety, perceived lack of benefit, preference of “natural” treatment in calcium and 
vitamin D, and complicated dosing instructions. 
Project Summary 
For the practice improvement project, attention was focused on an independent internal 
medicine clinic serving around 10,000 patients in a Midwestern community. A retrospective data 
analysis was performed. Chart reviews were completed to attempt to identify the reasons most of 
the internal medicine clinic’s patients with significant fracture risk are not receiving therapy for 
osteoporosis. Two interviews were conducted with healthcare provider key informants at the 
clinic to further evaluate the provider perspective on the issue. A meeting for the internal 
medicine clinic’s providers to attend was hosted. The results of the retrospective chart reviews 
and key informant interviews were presented at the meeting. Based on the results, a list of 
recommendations for improvement of treatment rates for patients with significant fracture risk 
was presented at the meeting. 
Results 
Results showed inconsistent documentation of patient treatment preferences and provider 
treatment decisions. Additional areas for improvement include patient and provider follow up 
treatment as well as patient education regarding the disease process and benefits of treatment. 
Results and recommendations for improvement were disseminated to providers at the clinic with 
feedback solicited. An electronic medical record change was implemented in order to improve 
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documentation of treatment decisions regarding osteoporosis or osteopenia. Patients with high 
fracture risk were flagged, prompting a response regarding reasons for discontinuation of 
previous therapy or why the patient is not currently on therapy.  
Recommendations 
Recommendations to the facility included improvement of documentation for provider or 
patient treatment decisions regarding elevated fracture risk. An electronic medical record change 
was implemented in order to improve the documentation process. Patient education was also in 
need of improvement, so a provider who was designated as a patient education expert regarding 
pharmacology treatment to reduce fracture risk was recommended. 
 
